PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.68%
Positive EBIT growth while AXSM is negative. John Neff might see a substantial edge in operational management.
22.68%
Positive operating income growth while AXSM is negative. John Neff might view this as a competitive edge in operations.
22.99%
Positive net income growth while AXSM is negative. John Neff might see a big relative performance advantage.
38.32%
Positive EPS growth while AXSM is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
38.32%
Positive diluted EPS growth while AXSM is negative. John Neff might view this as a strong relative advantage in controlling dilution.
24.80%
Share count expansion well above AXSM's 1.14%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
24.80%
Diluted share count expanding well above AXSM's 1.14%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
22.87%
Positive OCF growth while AXSM is negative. John Neff would see this as a clear operational advantage vs. the competitor.
22.60%
Positive FCF growth while AXSM is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13974.70%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
19.53%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
73.45%
Positive 3Y OCF/share CAGR while AXSM is negative. John Neff might see a big short-term edge in operational efficiency.
-5088.50%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
66.11%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
78.36%
Positive short-term CAGR while AXSM is negative. John Neff would see a clear advantage in near-term profit trajectory.
2877.65%
Equity/share CAGR of 2877.65% while AXSM is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
75.50%
Equity/share CAGR of 75.50% while AXSM is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
-75.29%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.74%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-36.19%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
-25.49%
Our R&D shrinks while AXSM invests at 16.79%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-16.18%
We cut SG&A while AXSM invests at 1.18%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.